Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate
Dermata Therapeutics, Inc. +3.15% Pre
Dermata Therapeutics, Inc.
DRMA
|
1.31
1.31
|
+3.15%
0.00% Pre |
Dermata Therapeutics (NASDAQ:
DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share from the same period last year.